Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,140 Mln
Revenue (TTM)
$478 Mln
Net Profit (TTM)
$13 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
86.7
P/B Ratio
2.6
Industry P/E
54.26
EV/EBITDA
21.9
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.4
Face value
--
Shares outstanding
34,582,900
CFO
$419.10 Mln
EBITDA
$368.50 Mln
Net Profit
$77.42 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Natus Medical (NTUS)
| 38.9 | 6.0 | -1.4 | 34.5 | 7.9 | -3.4 | 9.8 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Natus Medical (NTUS)
| 18.4 | -39.3 | -3.1 | -10.9 | 9.8 | -27.6 | 33.3 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Natus Medical (NTUS)
|
33.0 | 1,139.9 | 478.3 | 12.7 | 4.4 | 2.4 | 86.7 | 2.6 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection,... treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin. Read more
Pres, CEO & Director
Mr. Thomas Joseph Sullivan
Pres, CEO & Director
Mr. Thomas Joseph Sullivan
Headquarters
Middleton, WI
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Natus Medical Incorporated (NTUS) is $32.96 (NASDAQ) as of 21-Jul-2022 09:30 EDT. Natus Medical Incorporated (NTUS) has given a return of 7.88% in the last 3 years.
The P/E ratio of Natus Medical Incorporated (NTUS) is 86.74 times as on 21-Jul-2022, a 60 premium to its peers’ median range of 54.26 times.
The P/B ratio of Natus Medical Incorporated (NTUS) is 2.65 times as on 21-Jul-2022, a 10 discount to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
61.23
|
1.90
|
|
2020
|
-41.01
|
1.66
|
|
2019
|
-71.58
|
2.70
|
|
2018
|
-48.96
|
2.82
|
|
2017
|
-62.12
|
2.99
|
The 52-week high and low of Natus Medical Incorporated (NTUS) are Rs -- and Rs -- as of 04-Apr-2026.
Natus Medical Incorporated (NTUS) has a market capitalisation of $ 1,140 Mln as on 21-Jul-2022. As per SEBI classification, it is a company.
Before investing in Natus Medical Incorporated (NTUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.